IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
Zacks.com featured highlights include Lululemon Athletica, Sanderson Farms, IDEXX Laboratories and NVR
by Zacks Equity Research
Zacks.com featured highlights include Lululemon Athletica, Sanderson Farms, IDEXX Laboratories and NVR
Cooper Companies Buys Teva's PARAGARD Intrauterine Platform
by Zacks Equity Research
Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.
Ecolab (ECL) Features in DJSI List for Third Consecutive Year
by Zacks Equity Research
Ecolab???s (ECL) nomination as a leading player in the Dow Jones Sustainability Index will lend the company a leading position in the healthcare domain.
Buy These 4 Efficient Stocks for Healthy Returns
by Tirthankar Chakraborty
Companies with favorable efficiency levels are poised to be on investors' radar irrespective of market conditions
5 Top-Ranked MedTech Growth Stocks for Solid Returns
by Zacks Equity Research
Despite the ongoing turmoil in the MedTech industry, these stocks with high growth potential can be great bets for investors.
Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales
by Zacks Equity Research
Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.
Inogen (INGN) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Inogen (INGN) develops, manufactures and markets POCs. The company's direct-to-customer business model lent it a leading position in the oxygen therapy space.
Cooper to Benefit From Specialty Lenses Prospects Amid Woes
by Zacks Equity Research
The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.
Buy These 5 Large Caps on Extraordinary ROI Potential
by Zacks Equity Research
Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.
Boston Scientific Grows on Innovation, Buyouts Amid Woes
by Zacks Equity Research
While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.
Allscripts' (MDRX) dbMotion Platform Selected by SWSPHN
by Zacks Equity Research
The latest development is a significant addition to Allscripts' (MDRX) dbMotion Solution platform customer base. The company is poised to benefit from opportunities in the Asia-Pacific market.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife
by Zacks Equity Research
Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.
Medtronic (MDT) & Mazor Robotics Tie-Up Reaches Next Level
by Zacks Equity Research
With an investment of $40 million as a third installment in Mazor Robotics, Medtronic (MDT) will become the exclusive worldwide distributor of the Mazor X system.
Hologic (HOLX) Launches Brevera, Progresses in Breast Health
by Zacks Equity Research
Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
Mazor Robotics Hits 52-Week High Through Medtronic Alliance
by Zacks Equity Research
Mazor Robotics (MZOR) touched a new 52-week high on the back of favorable amendment of its strategic partnership with Medtronic.
GNC Holdings Gains on New GNC Strength Amid Soft Revenues
by Zacks Equity Research
GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.
3 MedTech Stocks Set to Rally in the Second Half
by Zacks Equity Research
The wide gamut of Medical Device presents interesting choice for investors to profit from rally in the second half of 2017.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Abbott's (ABT) FreeStyle Libre Gets Japan Reimbursement Nod
by Zacks Equity Research
Abbott's (ABT) diabetes care segment to further strengthen with the FreeStyle Libre glucose monitoring system's latest Japanese national reimbursement grant.
The Cooper Companies (COO) Beats Earnings Estimates in Q3
by Zacks Equity Research
The Cooper Companies (COO) provided strong guidance for fiscal 2017. However, the soft outlook for CooperSurgical indicates looming concerns.